We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

IMOS:NASDAQChipMOS TECHNOLOGIES INC. Analysis

Data as of 2026-07-31 - not real-time

$47.40

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

ChipMOS posted record quarterly revenue, delivering the highest monthly and quarter figures since 2014 and posting double‑digit year‑over‑year growth, which has helped lift the 20‑day SMA above both the 50‑day and 200‑day averages, suggesting a short‑term bullish bias. However, the stock trades at a trailing P/E of over 60 versus an industry average of 33, margins remain thin, free cash flow is negative, and the payout ratio hovers near 100%, raising concerns about dividend sustainability. Technicals are mixed: the RSI sits in the mid‑30s hinting at possible oversold conditions, while the MACD remains bearish with a widening negative histogram, and volume is trending down, indicating waning participation.
Given the high beta of around 2, extreme 30‑day volatility (>100%), and a recent max drawdown of roughly 40%, the equity carries significant market and liquidity risk. The combination of elevated valuation multiples, debt‑heavy balance sheet, and geopolitical exposure in Taiwan suggests a cautious stance, with upside limited to continued revenue momentum but downside potential if earnings fail to catch up.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Bullish moving‑average crossover (20‑day above 50‑day and 200‑day)
  • Bearish MACD histogram and line below signal
  • Decreasing volume indicating weakening buying pressure

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Strong revenue growth but thin margins and negative free cash flow
  • High valuation multiples relative to peers
  • Elevated beta and volatility amplifying market risk

Long Term

> 3 years
Cautious
Model confidence: 7/10

Key Factors

  • Overvaluation with P/E far above industry average
  • Heavy debt load and near‑full payout ratio threatening dividend durability
  • Geopolitical exposure in Taiwan and high sector cyclicality

Key Metrics & Analysis

Financial Health

Revenue Growth25.40%
Profit Margin3.25%
P/E Ratio61.6
ROE3.33%
ROA2.19%
Debt/Equity64.29
P/B Ratio2.2
Op. Cash Flow$3.3B
Free Cash Flow$-231215008
Industry P/E32.8

Technical Analysis

TrendBullish
RSI35.9
Support$43.51
Resistance$78.35
MA 20$62.53
MA 50$61.47
MA 200$41.87
MACDBearish
VolumeDecreasing
Fear & Greed Index92.88

Valuation

Fair Value$2,210.47
GradeOvervalued
TypeGrowth
Dividend Yield1.62%

Risk Assessment

Beta2.05
Volatility107.24%
Sector RiskHigh
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.